Scholar Rock

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Scholar Rock 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About SRRK

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. 

CEO
David L. Hallal
CEODavid L. Hallal
Employees
289
Employees289
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2012
Founded2012
Employees
289
Employees289

SRRK Key Statistics

Market cap
7.08B
Market cap7.08B
Price-Earnings ratio
-16.37
Price-Earnings ratio-16.37
Dividend yield
Dividend yield
Average volume
1.00M
Average volume1.00M
High today
$58.75
High today$58.75
Low today
$55.90
Low today$55.90
Open price
$56.80
Open price$56.80
Volume
931.99K
Volume931.99K
52 Week high
$58.75
52 Week high$58.75
52 Week low
$27.07
52 Week low$27.07

Stock Snapshot

With a market cap of 7.08B, Scholar Rock(SRRK) trades at $58.16. The stock has a price-to-earnings ratio of -16.37.

As of 2026-08-24, Scholar Rock(SRRK) stock has fluctuated between $55.90 and $58.75. The current price stands at $58.16, placing the stock +4.0% above today's low and -1.0% off the high.

Scholar Rock(SRRK) shares are trading with a volume of 931.99K, against a daily average of 1M.

In the last year, Scholar Rock(SRRK) shares hit a 52-week high of $58.75 and a 52-week low of $27.07.

In the last year, Scholar Rock(SRRK) shares hit a 52-week high of $58.75 and a 52-week low of $27.07.

SRRK News

Investing.com 2h
Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD - Investing.com

...

Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD - Investing.com
Simply Wall St 12h
Scholar Rock Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?

Earlier this week, Scholar Rock announced it had removed Catalent Indiana from all commercial fill-finish roles in apitegromab’s U.S. BLA for spinal muscular at...

Scholar Rock Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?
TipRanks 3d
Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

Scholar Rock (SRRK) announced it has removed Catalent Indiana (NVO) as a commercial fill-finish facility from its apitegromab Biologics License Application for...

Analyst ratings

100%

of 17 ratings
Buy
100%
Hold
0%
Sell
0%

More SRRK News

Nasdaq 7d
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

Scholar Rock (NASDAQ:SRRK) CEO David Hallal said the company is preparing for a September 30 FDA decision date for apitegromab, its investigational treatment fo...

Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab

People also own

Based on the portfolios of people who own SRRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.